ACE kinetic is FDA 510(k) cleared. For in vitro Diagnostic Use.
Health Canada License: HC80727
Automated Enzymatic Assay
Angiotensin Converting Enzyme
Elevated levels of serum ACE have been measured in patients suffering from various disorders. They often indicate a poor prognosis or rapid progression of the disease. Elevated serum ACE levels are reported in granulomatous-inflammatory diseases such as Sarcoidosis and Mixed-Connective-Tissue Disease (MTCD), Nephropathies associated with Diabetes and Glomerulonephritis, Cardiovascular diseases such as left ventricular hypertrophy, brain and myocardial infarction.
The main application is Sarcoidosis. Other areas of application are Chronic Berylliosis and monitoring of compliance under ACE inhibitor therapy.
High Sensitive Methods
|Time to result||10 min (approx.)|
|Sample type||25 µl serum|
|Sensitivity||12 ACE units|
|Catalog Number||see below|
|Status||FDA 510(k) cleared, IVD|
Consequently, diagnostic tools are essential to closely monitor disease activity and to predict disease progression. ACE is valuable to assess the disease activity, especially in systemic Sarcoidosis. It is released by epitheloid cells and its serum level correlates significantly with the granuloma burden of the patient.
The positive predictive value of elevated ACE activity is estimated between 75-90%, the negative predicted value between 70-80%. An initial low ACE activity indicates a good prognosis.